Lv2
108 积分 2025-07-17 加入
First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI)
21天前
已关闭
SCF and Cullin/Ring H2-based ubiquitin ligases
26天前
已完结
Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation
26天前
已完结
General room-temperature Suzuki–Miyaura polymerization for organic electronics
5个月前
已完结
Through-space interactions of optoelectronic materials
6个月前
已完结
Green Synthesis Method of Poly[(2,5-diyl pyrrole)(4-hydroxy-3-methoxy benzylidene)] Semiconductor Polymer Using an Ecologic Catalyst
6个月前
已完结
Thalidomide-targeted degradation
7个月前
已关闭
Near-infrared light controlled protein degradation by photo-caged lenalidomide and pomalidomide
7个月前
已完结
Emerging methods to improve PROTAC transport across cell membrane
7个月前
已关闭
Light‐Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy
10个月前
已完结
皖公网安备34019202002308
